


GANTENERUMAB PHASE 3 GRADUATE I AND GRADUATE II STUDIES

Two parallel, Phase 3, global, randomized placebo-controlled studies of gantenerumab in early Alzheimer's disease¹⁻⁷



Gantenerumab is investigational and has not been approved by the FDA. Efficacy and safety have not been established.

Studies WN39658 and WN29922. AD, Alzheimer's disease; ADAS-Cog13, 13-item Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS-ADL, Alzheimer Disease Cooperative Study–Activities of Daily Living; CDR-GS, Clinical Dementia Rating–Global Score; CSF, cerebrospinal fluid; FAQ, Functional Activities Questionnaire; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; MRI, Magnetic Resonance Imaging; OLE, open-label extension; PET, positron emission tomography; R, randomized

^aProbable AD dementia (consistent with NIA/AA core clinical criteria for probable AD dementia) or prodromal AD (consistent with the NIA/AA diagnostic criteria and guidelines for MCI due to AD). ^bThe inclusion criteria for FCSRT was Free recall ≤ 27 and Cueing index ≤ 0.67. ^cGRADUATE studies could be extended to 30 months in total, in the event that COVID-19-related interruptions in dosing and other study procedures worsen significantly.

1. Roche Investor Report. Available at: www.roche.com/investors.htm. Accessed July 22, 2021. 2. NIH. Available at: [NCT03443973](https://clinicaltrials.gov/ct2/show/study/NCT03443973). Accessed July 22, 2021. 3. NIH. Available at: [NCT03444870](https://clinicaltrials.gov/ct2/show/study/NCT03444870). Accessed July 22, 2021.

4. NIH. Available at: [NCT04374253](https://clinicaltrials.gov/ct2/show/study/NCT04374253). Accessed August 11, 2021. 5. Lane C, et al. Oral Presentation Presented at Clinical Trials on Alzheimer's Disease 2021, Boston, MA; November 9-12, 2021.

6. Pross N, et al. Presented at AD/PD 2019, March 26–31, Lisbon, Portugal; 7. Data on file.